Physician profile
Ted Du
NPI 1568526580
$4,425.99
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $425 · 2021: $293 · 2022: $433 · 2023: $617 · 2024: $1,023 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $614.11 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $561.16 | 2019-2025 | Xelpros, Cequa |
| Alcon Vision LLC | $504.76 | 2019-2025 | Simbrinza, Rocklatan, Rhopressa |
| Allergan, INC. | $384.45 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $286.55 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $256.80 | 2019 | |
| Bausch & Lomb Americas INC. | $237.47 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $230.72 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Harrow Eye, LLC | $229.35 | 2024-2025 | Vevye |
| Coopervision INC. | $199.08 | 2020-2025 | Misight Contact Lens, Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $176.31 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $169.11 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $158.70 | 2019 | |
| Horizon Therapeutics Plc | $134.79 | 2023 | Tepezza |
| Amgen INC. | $116.32 | 2024-2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $54.25 | 2020-2021 | |
| Thea Pharma INC. | $44.66 | 2023-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $27.20 | 2025 | Omidria |
| Halozyme INC | $21.22 | 2024 | Hylenex Recombinant |
| Merz North America, INC. | $18.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.